Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Anti-CCR4 CAR-T cells |
| Synonyms | |
| Therapy Description |
Anti-CCR4 CAR-T cells are T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CCR4 and contains 4-1BB costimulatory and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CCR4 and inhibit tumor growth (PMID: 37058474). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Anti-CCR4 CAR-T cells | Anti-CCR4 CAR-T cells are T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CCR4 and contains 4-1BB costimulatory and CD3zeta signaling domains, which potentially induce killing of tumor cells expressing CCR4 and inhibit tumor growth (PMID: 37058474). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07055477 | Phase I | Anti-CCR4 CAR-T cells Cyclophosphamide + Fludarabine | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | Recruiting | USA | 0 |